國家衛生研究院 NHRI:Item 3990099045/3028
English  |  正體中文  |  简体中文  |  全文筆數/總筆數 : 12340/13424 (92%)
造訪人次 : 2037072      線上人數 : 438
RC Version 6.0 © Powered By DSPACE, MIT. Enhanced by NTU Library IR team.
搜尋範圍 查詢小技巧：
  • 您可在西文檢索詞彙前後加上"雙引號"，以獲取較精準的檢索結果
  • 若欲以作者姓名搜尋，建議至進階搜尋限定作者欄位，可獲得較完整資料
    •  進階搜尋
    主頁 ‧ 登入 ‧ 上傳 ‧ 說明 ‧ 關於NHRI ‧ 管理 到手機版


    請使用永久網址來引用或連結此文件: http://ir.nhri.org.tw/handle/3990099045/3028


    題名: Gemcitabine versus the combination of cisplatin and etoposide in patients with inoperable non-small-cell lung cancer in a phase II randomized study
    作者: Perng, RP;Chen, YM;MingLiu, J;Tsai, CM;Lin, WC;Yang, KY;WhangPeng, J
    貢獻者: National Institute of Cancer Research
    摘要: Purpose: A phase II randomized study was conducted to evaluate the efficacy and toxicity of gemcitabine (GEM) versus the combination of cisplatin and etoposide (EP) in Chinese patients with inoperable (stage III or IV) non-small-cell lung cancer (NSCLC). Patients and Methods: From March 1995 to February 1996, 53 patients were enrolled onto the study: 27 onto the GEM arm and 26 onto the EP arm. In the GEM arm, gemcitabine 1,250 mg/m(2) was given as a 30-minute intravenous (IV) infusion on days 1,8, and 15 of each 28-day cycle. In the EP arm, cisplatin 80 mg/m(2) was given on day 1 and etoposide 80 mg/m(2) was given on days 1, 2, and 3 of each 28-day cycle. Results: Twenty-six patients are assessable for treatment response on the GEM arm and 24 on the EP arm. Five patients (19.2%) on the GEM arm and five patients (20.8%) on the EP arm achieved a partial response (PR). No complete responses were attained on either treatment arm. All patients enrolled onto the study were eligible for toxicity assessment. The main toxicities were myelosuppression and vomiting, which included World Health Organization (WHO) grade 3 or 4 leukopenia (3.7%), thrombocytopenia (7.4%), anemia (7.4%), and nausea/vomiting (3.7%) on the GEM arm, and WHO grade 3 or 4 leukopenia (30.8%), thrombocytopenia (7.7%), anemia (15.4%), and nausea/vomiting (34.6%) on the EP arm. The median survival time was 37 weeks on the GEM arm and 48 weeks on the EP arm. Conclusion: Gemcitabine is a well-tolerated chemotherapeutic agent for NSCLC. The antitumor activity was promising, with a 19.2% single-drug response rate, when compared with EP combination chemotherapy, which had a response rate of 20.8%. The safety profile is better than that of EP treatment.
    關鍵詞: Oncology
    日期: 1997-05
    關聯: Journal of Clinical Oncology. 1997 May;15(5):2097-2102.
    Link to: http://jco.ascopubs.org/cgi/content/abstract/15/5/2097
    JIF/Ranking 2023: http://gateway.webofknowledge.com/gateway/Gateway.cgi?GWVersion=2&SrcAuth=NHRI&SrcApp=NHRI_IR&KeyISSN=0732-183X&DestApp=IC2JCR
    Cited Times(WOS): https://www.webofscience.com/wos/woscc/full-record/WOS:A1997WZ56400049
    Cited Times(Scopus): http://www.scopus.com/inward/record.url?partnerID=HzOxMe3b&scp=0030900495
    顯示於類別:[彭汪嘉康(1996-2007)] 期刊論文
    [劉敏(1996-2007)] 期刊論文

    文件中的檔案:

    檔案 描述 大小格式瀏覽次數
    A1997WZ56400049.pdf490KbAdobe PDF303檢視/開啟


    在NHRI中所有的資料項目都受到原著作權保護.

    TAIR相關文章

    DSpace Software Copyright © 2002-2004  MIT &  Hewlett-Packard  /   Enhanced by   NTU Library IR team Copyright ©   - 回饋